These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. Sanborn RE; Ross HJ; Aung S; Acheson A; Moudgil T; Puri S; Hilton T; Fisher B; Coffey T; Paustian C; Neuberger M; Walker E; Hu HM; Urba WJ; Fox BA J Immunother Cancer; 2017 Dec; 5(1):103. PubMed ID: 29258618 [TBL] [Abstract][Full Text] [Related]
26. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616 [TBL] [Abstract][Full Text] [Related]
27. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring. Lilleby W; Seierstad T; Inderberg EM; Hole KH Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014 [TBL] [Abstract][Full Text] [Related]
28. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies. Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388 [TBL] [Abstract][Full Text] [Related]
29. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678 [TBL] [Abstract][Full Text] [Related]
30. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435 [TBL] [Abstract][Full Text] [Related]
31. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia. Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF Cancer; 2017 Aug; 123(16):3061-3072. PubMed ID: 28411378 [TBL] [Abstract][Full Text] [Related]
32. In Silico Approach in Designing a Novel Multi-Epitope Vaccine Candidate against Non-Small Cell Lung Cancer with Overexpressed G Protein-Coupled Receptor 56. Herrera LRM Asian Pac J Cancer Prev; 2020 Aug; 21(8):2297-2306. PubMed ID: 32856858 [TBL] [Abstract][Full Text] [Related]
34. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833 [TBL] [Abstract][Full Text] [Related]
35. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149 [TBL] [Abstract][Full Text] [Related]
36. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008 [TBL] [Abstract][Full Text] [Related]
37. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. Nemunaitis J; Sterman D; Jablons D; Smith JW; Fox B; Maples P; Hamilton S; Borellini F; Lin A; Morali S; Hege K J Natl Cancer Inst; 2004 Feb; 96(4):326-31. PubMed ID: 14970281 [TBL] [Abstract][Full Text] [Related]
38. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319 [TBL] [Abstract][Full Text] [Related]
39. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961 [TBL] [Abstract][Full Text] [Related]
40. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]